Pediatrix Medical's Q3 Test: Can Lower Expenses Drive Earnings?

Core Insights - Pediatrix Medical Group, Inc. (MD) is scheduled to report its Q3 2025 results on November 3, 2025, with earnings estimated at 46 cents per share and revenues at $484.1 million [1][8] - The earnings estimate reflects a year-over-year increase of 4.6%, while the revenue estimate indicates a decline of 5.3% compared to the previous year [2][8] Earnings Estimates - The earnings estimate for Q3 has remained stable over the past 60 days, with no revisions [2][3] - For 2025, the revenue estimate is projected at $1.89 billion, representing a 6% decline year-over-year, while the EPS for the current year is expected to grow by 17.9% to $1.78 [3] Historical Performance - Pediatrix Medical has consistently beaten consensus earnings estimates in the last four quarters, with an average surprise of 28.7% [4] Earnings Prediction Model - The current model does not predict an earnings beat for Q3, as the Earnings ESP is 0.00% and the Zacks Rank is 3 (Hold) [5] Q3 Factors - The Q3 EPS estimate of 46 cents suggests growth, but the revenue estimate of $484.1 million indicates a decline [8] - A projected 7.4% year-over-year decline in net patient service revenue and a 5.7% decline in hospital contract administrative fees are expected to impact the top line [9] Operating Expenses and Cash Flow - Total operating expenses are estimated to decline nearly 11% year-over-year, aided by lower practice salaries, benefits, and G&A costs [11] - The estimated operating cash flow for Q3 is projected to be approximately $121 million, showing significant improvement from the previous year [11] Industry Context - Other companies in the medical sector, such as HCA Healthcare, Universal Health Services, and Community Health Systems, have reported their earnings, showcasing varied performance metrics [12][13][14][15]